Healthcare Business Recap: Dendreon Investigation Chatter, Rosetta Genomics Rockets
An FDA advisory panel clears the way for an HIV test be sold in retail stores, and shares of OraSure Technologies (NASDAQ:OSUR) take off. The panel voted 17 to 0 in favor twice, saying that potential benefits outweigh the risks, and also voted on effectiveness and safety. The test results could be read similarly to those for pregnancy and blood sugar.
Investing Insights: Late Radar Stocks: Limited Brands Declines 3.5%, Einhorn Quiet on Herbalife.
Shares of microRNA-based molecular diagnostic test maker Rosetta Genomics (NASDAQ:ROSG) close more than 200 percent higher Wednesday, following word that all Medicare beneficiaries will be covered by Rosetta’s miRview® mets² assay. Novitas, the designated Medicare Administrative Contractor for the assay, made the announcement.
Unconfirmed chatter that the SEC has opened an inquiry on Dendreon’s (NASDAQ:DNDN) disclosures, sent shares lower after hours on Wednesday. The firm did not reveal the SEC probe in its tenth quarter filing on May 7th, but some details might be getting out.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Don’t Miss: Home Builders Continue to Think Happy Thoughts.